stockportfolio.pro
BAX vs CRL: Which Stock Is the Better Buy?
Baxter International Inc. and Charles River Laboratories International, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BAX vs CRL, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Baxter International Inc. (BAX) | Charles River Laboratories International, Inc. (CRL) | |
|---|---|---|
| Market cap | $11.7B | $11.1B |
| Revenue (latest FY) | $11.24B | $4.02B |
| Net income (latest FY) | $-957.00M | $-144.34M |
| Revenue growth (5y CAGR) | -0.7% | 6.5% |
| Net margin | -8.5% | -3.6% |
| Return on equity | -15.6% | -4.6% |
| P/E ratio | — | — |
| Dividend yield | 0.9% | — |
| Profitable years (of last 10) | 7 | 9 |
| Positive free cash flow | Yes | Yes |
See the full BAX vs CRL breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BAX's full financials → Open CRL's full financials →More comparisons
Frequently asked questions
Which is bigger, BAX or CRL?
Baxter International Inc. is larger by market capitalization — $11.7B versus $11.1B.
Which grows faster, BAX or CRL?
Over the last five fiscal years, Charles River Laboratories International, Inc. grew revenue faster — 6.5%/yr versus -0.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.